Meningococcal Vaccine Market Size, Share, By Vaccine Type (Conjugative, Polysaccharide, and Others), Serotype (Serotype A, Serotype B, Serotype C, Serotype W, and Serotype Y), Age Group (Infants, Children and Adults), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Healthcare Institutions, and Others) and Region - Trends, Analysis, and Forecast till 2035

Meningococcal Vaccine market size was valued at USD 3.5 Billion in 2025 and is expected to reach USD 6.1 Billion by 2035, growing at a CAGR of 6.3%

The meningococcal vaccination guards against the pathogenic agent Neisseria meningitides, which can cause meningitis and septicemia, among other serious illnesses. Meningococcal conjugate vaccines (MenACWY), which offer protection against serotypes A, C, W, and Y, and Meningococcal B vaccine (MenB), which offers protection against serotype B, are the two main types of meningococcal vaccinat.

Technological advancement in new vaccine technologies, and approval to new vaccines from regulatory bodies, is projected to growth of meningococcal vaccine market share. The increasing demand for meningococcal vaccines for travelers, high-risk population, introduction of combination vaccines, and increasing focus on preventive healthcare, is expected to boost meningococcal vaccine market size. Many government and global health organization such as WHO, are introducing new vaccines against meningitis and septicemia to distribute vaccines in low & middle income countries, is anticipated to drive target market growth.